Assessment of Clinical Trial Experiences of Alzheimer's Disease Patients

Alzheimer Disease Clinical Trial

Official title:

In Depth Observational Clinical Trial Assessing Experiences of Alzheimer's Disease Patients To Determine Trial Attributes Affecting Completion Rates For Specific Demographic Groups

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05672732
• Other study ID #: 81466128
• Status: Not yet recruiting
• Start date: February 2024
• Est. completion date: February 2026

Study information

• Verified date: June 2023
• Source: Power Life Sciences Inc.
• Contact: Michael B Gill
• Phone: 415-900-4227
• Email: bask[@]withpower.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This study will admit a wide range of data on the clinical trial experience of Alzheimer's Disease patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Alzheimer's Disease patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: February 2026
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patient is at least 50 to 80 years of age

• Participant has a diagnosis of Alzheimer's Disease

• Patient has self-identified as planning to enroll in an interventional clinical trial for Alzheimer's Disease

Exclusion Criteria:

• No diagnosis of Alzheimer's Disease confirmed

• Inability to perform regular electronic reporting

• Patient does not understand, sign, and return consent form

Related Conditions & MeSH terms

• Alzheimer Disease

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Power Life Sciences Inc.

References & Publications (3)

Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JC. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry. 2018 Aug;26(4):347-357. doi: 10.1177/1039856218762308. Epub 2018 Apr 3. — View Citation

Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010 Jul;9(7):702-16. doi: 10.1016/S1474-4422(10)70119-8. Erratum In: Lancet Neurol. 2011 Jun;10(6):501. — View Citation

Rafii MS, Aisen PS. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs. 2019 Feb;33(2):99-106. doi: 10.1007/s40263-018-0598-1. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of patients who decide to enroll in a Alzheimer's Disease Clinical Trial		3 months
Primary	Number of patients who remain in Alzheimer's Disease clinical trial until completion		12 months